Page 61 - Boxed Warning News Today

Press release content from Business Wire. The AP news staff was not involved in its creation.

Share this article Share this article CUPERTINO, Calif., June 9, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 The first poster will discuss additional efficacy signals from a Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients. Previously reported data showed that DUR-928 was well tolerated at all three doses evaluated, 50mg QD, 150mg QD, and 300mg BID (600mg/day) with overall ...

71% of Adult Patients in Phase 2 ZUMA-3 Study Achieved a Complete Response Following a Single Infusion of Tecartus -- - -- If Approved, Tecartus Would Be the First and Only CAR T-Cell Therapy Approved for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia -- Kite, a Gilead Company announced today results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, ...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present data from post-hoc analyses that suggested OLUMIANT® (baricitinib) 4...

-- New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Less Weight Gain -- -- Commercial Launch Planned for Fourth Quarter 2021 -- -- Company to Host Investor

Qelbree (viloxazine extended-release capsules) is now available for attention-deficit hyperactivity disorder in patients 6 to 17 years of age.

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved LYBALVI™ (olanzapine and samidorphan)...

Search jobs 27-May-2021 Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated with Uterine Fibroids In the Phase 3 LIBERTY 1 and LIBERTY 2 studies, MYFEMBREE demonstrated 72.1% and 71.2% response rates in menstrual blood loss (MBL) at Week 24, with MBL reductions of 82.0% and 84.3% from baseline Myovant and Pfizer will jointly commercialize MYFEMBREE, with product avai...

Zogenix Launches Dravet Syndrome Community Photo Sharing Charitable Campaign and Contest to Benefit the Dravet Syndrome Foundation and the Epilepsy Foundation News provided by Share this article FINTEPLA EMERYVILLE, Calif., May 19, 2021 /PRNewswire/ -- Zogenix, a global biopharmaceutical company developing rare disease therapies, today launched the FINTEPLA Photo Diary, a community sharing, charitable campaign and contest. To participate in the charitable campaign and contest, Zogenix is askin...

Feeling of blacking out It’s important to take steps to capture these symptoms when you feel them. What were you doing? Were you standing or sitting? What time of day was it? A symptoms tracker may be helpful and serve as a tool to use when talking with your doctor. How is nOH Treated? There are a variety of lifestyle changes that may help ease the symptoms of nOH, like drinking two glasses of water, increasing your salt intake or wearing abdominal binders. In addition to lifestyle changes...